The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices

被引:0
作者
Padgett, Tonja M. [1 ]
机构
[1] Indiana Univ, Sch Nursing, 600 Barnhill Dr,NUE429, Indianapolis, IN 46204 USA
关键词
medication-assisted treatment; opioid use disorder; primary care; substance use disorder; OPIOID DEPENDENCE; BUPRENORPHINE; SUBSTANCE; METHADONE; NEED;
D O I
10.1097/JAN.0000000000000305
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Substance use disorder (SUD), more specifically opioid use disorder, is a national epidemic. Although there is an emphasis on treatment and increasing treatment locations, there continues to be a gap between the number of people with SUD and the number of treatment centers. To help narrow this gap, some primary care clinicians started providing medication-assisted treatment (MAT) on an outpatient basis in their offices. This option enables clinicians to provide treatment in their own communities, which increases access to treatment and decreases costs. It also enables the clinician and the person with SUD/opioid use disorder to build a relationship, which many clinicians believe is the foundation of successful treatment. The clinician, whether a doctor, a physician assistant, or an advanced practice nurse, has to obtain a Drug Addiction Treatment Act 2000 waiver to provide MAT beyond naltrexone, which has a required educational program and includes a limitation on the number of clients. Conversely, a possible drawback to this type of treatment is the potential for the disruption of continuity of care with regard to psychotherapy treatment. Federal law mandates that therapy is available and provided to people receiving MAT. The clinician may not be able to provide this service and would need to refer the person with SUD for psychotherapy treatment. It may be clinically significant for a type of follow-up communication to be implemented so that the clinician and the therapy provider can maximize SUD treatment success.
引用
收藏
页码:238 / 241
页数:4
相关论文
共 23 条
[1]   Outcomes from the International Survey Informing Greater Insights in Opioid Dependence Treatment (INSIGHT) project [J].
Abagiu, Adrian Octavian ;
Cavar, Zrinka ;
Dannon, Pinhas ;
George, Philip ;
Habrat, Boguslaw ;
Mahomedy, Zubeida ;
Popov, Petr ;
Sarasvita, Riza ;
Utami, Diah Setia ;
Kastelic, Andrej .
DRUGS-EDUCATION PREVENTION AND POLICY, 2014, 21 (06) :440-450
[2]   Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience [J].
Amass, L ;
Ling, W ;
Freese, TE ;
Reiber, C ;
Annon, JJ ;
Cohen, AJ ;
McCarty, D ;
Reid, MS ;
Brown, LS ;
Clark, C ;
Ziedonis, DM ;
Krejci, J ;
Stine, S ;
Winhusen, T ;
Brigham, G ;
Babcock, D ;
Muir, JA ;
Buchan, BJ ;
Horton, T .
AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 :S42-S66
[3]   Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification [J].
Amato, Laura ;
Minozzi, Silvia ;
Davoli, Marina ;
Vecchi, Simona .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (09)
[4]  
[Anonymous], 2017, DETERMINATION PUBLIC
[5]  
[Anonymous], CURRENT PSYCHIAT
[6]  
[Anonymous], 2017, NCHS DATA BRIEF
[7]  
[Anonymous], 2018, COMBATING OPIOID EPI
[8]   Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians [J].
Arfken, Cynthia L. ;
Johanson, Chris-Ellyn ;
di Menza, Salvatore ;
Schuster, Charles Roberts .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 39 (02) :96-104
[9]   Estimating demand for primary care-based treatment for substance and alcohol use disorders [J].
Barry, Colleen L. ;
Epstein, Andrew J. ;
Fiellin, David A. ;
Fraenkel, Liana ;
Busch, Susan H. .
ADDICTION, 2016, 111 (08) :1376-1384
[10]  
Brezing C., 2015, Psychiatric Times, V32, P16